source
- Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trialSolstice Oncology, a cancer-focused startup that emerged from stealth in February, announced a $225 million Series A financing round to fund its early-stage programs. The capital will be used to a…
- Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic diseaseCaspian Therapeutics, a spin‑out from Kura Oncology, announced it is starting operations with $50 million in financing. The capital, led by BVF Partners and joined by Eli Lilly and Kura leadership,…